局解手术学杂志Issue(2)：160-161,162,3.DOI:10.11659/jjssx.01E014060
DPP4抑制剂沙格列汀对2型糖尿病患者体质量影响的临床观察
DPP4 inhibitor saxagliptin impact the body weight of patients with type 2 diabetes clinical observation
摘要
Abstract
Objective To observe the impact of DPP4 inhibitor Saxagliptin on body weight of type 2 diabetes patients. Methods In this randomized and parallel study,50 patients were given either Saxagliptin(n=25)or Glimepiride(n=24). The changes of body weight, HbA1c and hypoglycemic events were observated in 12 weeks. Results There were no significant difference in gender,age and body weight between 2 groups(P>0. 05). After 12 weeks treatment,body weight has significant changed in both group,and the weight changes were sig-nificant differet in two groups:an average of 0. 4 kg weight was increased in Glimepiride group and 0. 4 kg weight was decreased in Saxagliptin group (P<0. 05). The change of HbA1c level has no statistical difference in two groups (P>0. 05). Hypoglycemia event was happened four times in Glimepiride group,while no hypoglycemia event was happened in Saxagliptin group. Conclusion Compared with Glimepiride,Saxa-gliptin provides similar hypoglycemic action with less hypoglycemia,at the same time,Saxagliptin yields better results in lowering weight.关键词
DPP4抑制剂/沙格列汀/体质量/2型糖尿病Key words
DPP4 inhibitor/Saxagliptin/body weight/type 2 diabetes分类
医药卫生引用本文复制引用
张瑞,童强,管凌志..DPP4抑制剂沙格列汀对2型糖尿病患者体质量影响的临床观察[J].局解手术学杂志,2015,(2):160-161,162,3.基金项目
国家自然科学基金青年科学基金项目(81401601) （81401601）
